About this document
FOLFIRI vs. Irinotecan in mCRC Trial by Shashank Shekhar is a document available to read on EtoBox.
A randomized clinical trial comparing FOLFIRI (folinic acid, fluorouracil, and irinotecan) to single-agent irinotecan in metastatic colorectal cancer patients found no significant difference in progression-free survival, overall survival, or objective response rates between the two treatments. However, FOLFIRI was associated with higher toxicity rates, suggesting that single-agent irinotecan may be a more favorable second-line chemotherapy option for patients who failed first-line treatments. This study hig
- Author
- Shashank Shekhar
- Language
- EN